Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.74) earnings per share (EPS) for the quarter, Zacks reports.
Scinai Immunotherapeutics Stock Down 2.8%
Shares of SCNI stock opened at $3.13 on Tuesday. The stock’s fifty day moving average price is $2.66 and its 200 day moving average price is $4.98. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.35 and a quick ratio of 1.35. The company has a market cap of $1.63 million, a price-to-earnings ratio of -2.95 and a beta of 2.08. Scinai Immunotherapeutics has a 1-year low of $2.15 and a 1-year high of $16.80.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Scinai Immunotherapeutics presently has a consensus rating of “Sell”.
Institutional Investors Weigh In On Scinai Immunotherapeutics
A hedge fund recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC raised its position in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) by 146.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the quarter. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent SEC filing. Institutional investors own 58.41% of the company’s stock.
Scinai Immunotherapeutics Company Profile
Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.
Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.
Featured Stories
- Five stocks we like better than Scinai Immunotherapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
